Phase 1 N=200 Oral Tolerability Of Two Nicotine Dosage Forms
Healthy Volunteer Smokers
Primary: Percentage of Participants With Oral Soft Tissue Related Adverse Events at Week 1 — 2.3; 12.6 Percentage
Clinical Trial Search
Completed trials with posted results — search by concept, filter by the parameters that matter at the bedside.
Phase 1 N=40 A Study to Assess the Effect of Ustekinumab (Stelara®) and Etanercept (Enbrel®) in Participants With Moderate to Severe Psoriasis (MK-0000-206)
Psoriasis
Primary: Change From Baseline in Composite Gene Expression Score Based on IL-12 Pathway Related Interferon Gamma (IFN-γ)-Modulated Genes in Psoriatic Lesions of Participants…
Phase 1 N=47 CP-751,871 Treatment For Patients With Multiple Myeloma
Multiple Myeloma
Primary: Maximum Tolerated Dose (MTD) — NA mg/kg
Phase 1 N=46 Study Of CP-751,871 In Combination With Cisplatin And Gemcitabine In Chemotherapy-Naïve Patients With Advanced Non-Small Cell Lung Cancer
Carcinoma, Non-Small-Cell Lung
Primary: Number of Participants With Dose-limiting Toxicities (DLT) — 0; 0; 1 participants
Phase 1 N=223 A Study of Intradermal Administration of ZOSTAVAX™ (V211-051 AM2)
Herpes Zoster
Primary: Geometric Mean Fold Change From Baseline in Varicella Zoster Virus (VZV)-Specific Antibodies — 1.74; 1.64; 3.24; 2.45 Geometric mean fold change
Phase 1 N=59 Multiple Dose Escalation Study In Medically Stable Subjects With Psoriasis
Psoriasis · Immunomodulation
Primary: Change From Baseline in QT Interval at 1 Hour Post Morning Dose (HPD 1) on Day 1 — 372.20; 348.47; 369.40; 375.74 millisecond (msec)
Phase 1 N=9 Pharmacokinetics of Ceftaroline in Subjects 12 to 17 Years of Age
Infection
Primary: The Maximum Plasma Concentration (Cmax) of Ceftaroline After Administration of Ceftaroline Fosamil at a Dose of 8 mg/kg up to a Maximum Dose of 600 mg Via IV Infusion…
Phase 1 N=42 A Bioequivalence and Food Effect Study of SEP-190 in Japanese Healthy Subjects (Study SEP 190-102)
Insomnia
Primary: Pharmacokinetic Parameter (Bioequivalence): Maximal Drug Concentration (Cmax) — 40.80; 40.21 ng/mL
Phase 1 N=51 Study Evaluating SKI-606 (Bosutinib) In Advanced Malignant Solid Tumors
Neoplasms
Primary: Number of Participants With Dose-limiting Toxicities (DLT) in Part 1 — 0; 0; 1; 1 participants
Phase 1 N=78 Pharmacokinetic Study Comparing Blood Levels of Dasatinib in Healthy Participants Who Received the Tablet Formulation With Those Who Received Liquid and Tablet-dispersed Formulations
Pharmacokinetic Study in Healthy Participants
Primary: Maximum Observed Concentration (Cmax) of Dasatinib — 114; 106; 110 ng/mL
Phase 1 N=12 Oral Ketamine for Control of Chronic Pain in Children
Chronic Pain
Primary: Number of Participants Tolerating Dose — 3; 3; 3; 1 participants
Phase 1 N=30 Safety and Pharmacokinetics Study of Intranasal Ketorolac in Elderly and Nonelderly Adult Healthy Subjects
Healthy Subjects
Primary: Cmax (Maximum Plasma Concentration) — 1782.286; 1840.111 ng/mL
Phase 1 N=12 Radiation Therapy, Paclitaxel, and Cisplatin in Treating Patients With Cancer of the Cervix
Cervical Cancer
Primary: Dose Limiting Toxicity(DLT)/Significant Dose Delay of Paclitaxel With Cisplatin as Assessed by CTC 2.0 After 6 Cycles of Treatment — 0; 0; 2; 2 participants
Phase 1 N=30 Autologous Stem Cells for Cardiac Angiogenesis (FOCUS HF)
Ischemic Cardiomyopathy
Primary: Safety of Autologous-bone-marrow Injections — 1; 1; 0; 1 participants
Phase 1 N=46 A Study to Evaluate the Safety, Tolerability, and Pharmacokinetics of Inhaled Montelukast (MK-0476) in Participants With Mild or Moderate Asthma (MK-0476-380 AM3)(COMPLETED)
Asthma
Primary: Number of Participants Who Experienced At Least One Adverse Event — 2; 4; 6; 9 participants